肺泡表面活性物质治疗新生儿呼吸窘迫综合征的临床探讨

目的探讨肺泡表面活性物质(PS)治疗新生儿呼吸窘迫综合征(NRDS)的临床疗效。方法对11例NRDS患儿气管内注入固尔苏,观察治疗前后临床效果、血气和X线胸片。结果11例患儿中9例呼吸窘迫症状明显减轻,应用PS后1 h PaO2明显升高,有8例(72.7%)两肺野透亮度明显改善,2例轻度改善,1例4级白肺无改善。结论PS治疗新生儿呼吸窘迫综合征,早期足量应用可取得明显临床效果,缩短病程,降低NRDS病死率。

The Clinical Effect of Pulmonary Surfactant on Neonatal Respiratory Distress Syndrome

Objective To study the clinical efficacy of pulmonary surfactant(PS) on neonatal respiratory distress Syndrome(NRDS).Methods 11 NRDS infants were treated with PS(in bronchus),the change of the clinical effects,blood gas analysis and chest X-ray were observed before and after treatment.Results 9 of 11 NRDS infants' symptoms of respiratory distress decreased markedly,1 hour after the administration,PaO_2 of the NRDS infants was increased rapidly,chest X-ray showed that: Obvious improvement occurred in 8 patients(72.7%),2 patients had slight improvement,1 case had not any improvement.Conclusions PS should be used early and enough,it is effective on clinical respiratory distress,and it can reduce the course of disease and mortality of NRDS.